Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Yaffe Kristine reported acquisition or exercise transactions in this Form 4 filing.
Alector director Kristine Yaffe received new equity awards as part of her compensation. She was granted 28,700 restricted stock units representing shares of common stock, which vest on the earlier of June 17, 2027 or the date of Alector’s next annual meeting of stockholders.
She also received stock options for 9,450 shares of common stock, expiring on June 16, 2036. These options vest in 12 equal monthly installments beginning July 17, 2026, or fully on the earlier of the one-year anniversary of the grant date or the next annual meeting. Following the RSU grant, she directly holds 124,109 shares of common stock.
SCHELLER RICHARD H reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Richard H. Scheller reported equity compensation awards. He received 28,700 shares of Common Stock in the form of restricted stock units that vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. Following this grant, he directly holds 134,899 shares of common stock.
He was also granted a stock option for 9,450 shares of common stock. This option vests in 12 equal monthly installments beginning July 17, 2026, or fully on the earlier of the one-year anniversary of grant or the next annual meeting, and expires on June 16, 2036.
Hammond Paula reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Paula Hammond received new equity awards in the form of restricted stock units and stock options. She was granted 28,700 RSUs that vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. She also received a stock option covering 9,450 shares of common stock, vesting in 12 equal monthly installments beginning July 17, 2026, with full vesting no later than the earlier of one year from grant or the next annual meeting. Following these awards, Hammond directly holds 103,609 shares of Alector common stock.
Alector, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders elected three Class II directors—Elizabeth Garofalo, M.D., Errol De Souza, Ph.D., and Kristine Yaffe, M.D.—to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified Ernst & Young LLP as Alector’s independent registered accounting firm for the fiscal year ending December 31, 2026, with 97,717,750 votes in favor. In addition, shareholders approved, on a non-binding advisory basis, the compensation of Alector’s named executive officers in the Say-on-Pay vote, with 58,652,335 votes for and 2,492,538 against.
GAROFALO ELIZABETH A. reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Elizabeth A. Garofalo received new equity compensation on June 17, 2026. She was granted 28,700 shares of Common Stock in the form of restricted stock units that vest on the earlier of June 17, 2027 or the date of Alector’s next annual stockholder meeting.
On the same date, she was also granted stock options covering 9,450 shares of Common Stock. These options vest in 12 equal monthly installments beginning July 17, 2026, with full vesting on the earlier of the one-year anniversary of grant or the next annual stockholder meeting, and expire on June 16, 2036. Following these awards, she directly holds 118,650 shares of Common Stock and 9,450 stock options.
Altmeyer Mark reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Mark Altmeyer reported equity awards consisting of restricted stock units and stock options. He received 28,700 RSUs representing shares of common stock, which vest on the earlier of June 17, 2027 or the company’s next annual stockholder meeting. He was also granted options for 9,450 shares of common stock, vesting in 12 equal monthly installments beginning July 17, 2026, or in full on the earlier of one year from grant or the next annual meeting. Following these awards, he directly holds 98,650 shares of common stock and 9,450 stock options.
DESOUZA ERROL B reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Errol B. DeSouza received equity compensation consisting of restricted stock units and stock options. He was granted 28,700 RSUs representing common stock, bringing his direct common stock holdings to 98,650 shares after the award.
The RSUs vest on the earlier of June 16, 2027 or Alector’s next annual stockholder meeting. DeSouza was also granted options over 9,450 shares of common stock, which vest in 12 equal monthly installments beginning July 17, 2026, and fully vest on the earlier of the one-year anniversary of grant or the next annual meeting, and expire on June 16, 2036.
LAVIGNE LOUIS J JR reported acquisition or exercise transactions in this Form 4 filing.
Alector, Inc. director Louis J. Lavigne Jr. reported new equity compensation awards. He received 28,700 shares of common stock in the form of restricted stock units (RSUs) at no cost. These RSUs vest on the earlier of June 17, 2027 or Alector’s next annual meeting of stockholders.
He was also granted a stock option covering 9,450 shares of common stock, vesting in 12 equal monthly installments beginning July 17, 2026, with full vesting on the earlier of the one-year anniversary of grant or the next annual meeting. The option expires on June 16, 2036. Following these grants, he holds 128,109 common shares directly and 10,552 common shares indirectly through Lavrite, LLC, for which he serves as managing director.
SCHELLER RICHARD H reported acquisition or exercise transactions in this Form 4 filing.
Alector director Richard H. Scheller received an equity grant of 10,833 shares of Common Stock in the form of restricted stock units. These RSUs vest in four equal quarterly installments beginning on June 1, 2026. After this award, he holds 106,199 shares directly.
Alector, Inc. Chief Executive Officer Arnon Rosenthal reported a disposition of 87,216 shares of common stock on June 2, 2026 at a weighted average price of $1.9743 per share. The shares were sold to satisfy tax obligations from vesting restricted stock units, leaving him with 2,367,206 shares held directly, plus additional indirect holdings through family trusts.